CIRS Group will host the “2026 Global Food Regulations Annual Forum” in Shanghai, Seoul and Tokyo in June 2026. This conference will bring together leading experts from China, the US, Europe, Japan and South Korea to provide a comprehensive overview of the latest global regulatory developments.

CIRS EU, the European subsidiary of CIRS Group, will be exhibiting at Vitafoods Europe in Barcelona, Spain, from May 5–7, 2026 (Booth No.: 6D84M, Hall 6) . CIRS has participated in Vitafoods Europe multiple times in Geneva, and attended the 2025 event in Barcelona. This year, we will once again be present at Vitafoods Europe 2026. We sincerely invite both new and existing partners to join us for discussions and to explore collaboration opportunities together. We look forward to seeing you there.

As of March 31, 2026, a total of 20 Foods for Special Medical Purposes (FSMPs) were approved in the first quarter of 2026, bringing the cumulative number of approved FSMPs in China to 310.

As of March 31, 2026, based on publicly available information from the EU information retrieval platform (Open EFSA), CIRS has performed a statistical review of novel food (NF) application trends in the European Union (EU) for the first quarter of 2026.

In recent years, the number of GRAS notice submitted to the U.S. FDA has been on a steady upward trend. Since 2026, the U.S. FDA has been continuously updating its inventory of GRAS notice. CIRS Group has conducted a detailed statistical analysis and summary of FDA GRAS notice from January 2026 to March 2026, which is provided here for companies’ reference.

On April 2, 2026, the State Administration for Market Regulation released the “Catalog of Health Food Ingredients: Lycopene (Draft for Public Comment)”. The deadline for submitting comments and suggestions is May 10, 2026.

Recently, China's State Administration for Market Regulation (SAMR) released the “Catalog of Health Food Ingredients: Lycopene (Draft for Public Comment),” proposing to include lycopene in the catalog of health food ingredients and soliciting public feedback.

On March 31, 2026, the Food Standards Australia New Zealand (FSANZ) has decided to abandon the proposal pursuant to section 56 of the Food Standards Australia New Zealand Act 1991 (the FSANZ Act).

At the request of the European Commission, the Panel on Nutrition, Novel Foods, and Food Allergens (NDA) of the European Food Safety Authority (EFSA) was tasked with providing an opinion on the use of carbon dioxide extract from Cannabis sativa L. as a novel food under Regulation (EU) 2015/2283.

CIRS Group has compiled and summarized the intended uses and use levels of HMOs approved in the EU for industry reference. Among them, chemically synthesized and microbially produced 2’-FL have identical scope of use and use levels; similarly, chemically synthesized and microbially produced LNnT share the same conditions of use. The remaining HMOs are produced via microbial sources, and their intended uses may vary depending on the production organism.